← Research Journal

Research Review

CJC-1295 and Ipamorelin: Growth Hormone Peptide Research Overview

CJC-1295 and Ipamorelin are frequently studied in combination due to their complementary mechanisms of action in growth hormone secretion research. This overview explores what the preclinical literature reveals.

Futura Biolabs Research·May 15, 2025·9 min read

Growth hormone (GH) secretion is a tightly regulated process governed by the interplay of two hypothalamic hormones: growth hormone-releasing hormone (GHRH) and somatostatin. CJC-1295 and Ipamorelin represent two distinct classes of research peptides that target different points in this regulatory axis.

CJC-1295: A GHRH Analogue

CJC-1295 is a synthetic analogue of GHRH, modified to resist enzymatic degradation. The Drug Affinity Complex (DAC) formulation of CJC-1295 incorporates a lysine modification that allows it to bind to serum albumin, dramatically extending its half-life from minutes to several days in animal models.

Research has demonstrated that CJC-1295 stimulates growth hormone secretion in a dose-dependent manner while maintaining normal pulsatile GH release patterns. This distinction from continuous GH administration has been a focus of researchers studying physiological versus supraphysiological GH profiles.

Ipamorelin: A Selective GH Secretagogue

Ipamorelin is a pentapeptide ghrelin mimetic and growth hormone secretagogue. Its high selectivity for GH release — with minimal stimulation of cortisol, prolactin, or ACTH — distinguishes it from earlier generation secretagogues in research settings.

Studies utilising Ipamorelin in animal models have documented significant increases in GH secretion following administration, with effects lasting several hours. The selectivity profile makes it particularly useful for research designs requiring isolated GH axis stimulation without confounding hormonal responses.

The Combination Research Model

Much of the published preclinical work on CJC-1295 and Ipamorelin examines them in combination. The rationale: CJC-1295 increases the amplitude of GH pulses by stimulating GHRH receptors, while Ipamorelin amplifies pulsatile release through the ghrelin receptor. The result in animal models is a synergistic increase in GH secretion.

Researchers interested in this combination should ensure they are working with high-purity, independently verified peptides with separate CoA documentation for each compound.

For laboratory research purposes only. Not intended for human use.

Research Disclaimer

All content published by Futura Biolabs is intended for informational purposes relating to laboratory research only. The compounds discussed are not approved for human use, are not intended to diagnose, treat, cure, or prevent any disease, and should only be handled by qualified researchers in appropriate laboratory settings.